Introduction
Methods
Results
Baseline characteristics | Ely study | EGIR RISC study | ||
---|---|---|---|---|
Men | Women | Men | Women | |
n
| 356 | 515 | 534 | 692 |
Age (years) | 54.3 (53.4–55.1) | 53.3 (52.6–53.9) | 43.2 (42.5–43.9) | 44.4 (43.8–45.1) |
BMI (kg m−2) | 25.9 (25.6–26.2) | 25.6 (25.2–26.0) | 26.4 (26.1–26.6) | 24.8 (24.4–25.1) |
Fasting insulin (pmol/l)a
| 39.0 (36.9–41.2) | 38.2 (36.5–40.0) | 32.9 (31.4–34.4) | 29.2 (28.1–30.4) |
Fasting triacylglycerols (mmol/l)a
| 1.35 (1.28–1.42) | 1.11 (1.06–1.16) | 1.12 (1.08–1.17) | 0.85 (0.82–0.88) |
Fasting glucose (mmol/l) | 5.82 (5.77–5.87) | 5.60 (5.56–5.65) | 5.22 (5.17–5.26) | 4.94 (4.90–4.99) |
HOMA-Sa
| 131.9 (124.7–139.4) | 135.9 (129.7–142.4) | 160.5 (153.5–167.8) | 183.1 (176.1–190.5) |
Leptin (ng/ml)a
| 3.69 (3.35–4.07) | 13.84 (12.88–14.86) | 4.01 (3.64–4.40) | 14.62 (13.75–15.54) |
Adiponectin (µg/ml)a
| 5.23 (4.99–5.47) | 8.22 (7.90–8.55) | 6.07 (5.88–6.26) | 9.24 (8.97–9.50) |
LARa (ng/µg)a
| 0.71 (0.63–0.79) | 1.68 (1.54–1.84) | 0.66 (0.60–0.73) | 1.58 (1.47–1.70) |
Clamp M/I (μmol min−1 kg FFM−1 nmol−1)a
| 110.8 (106.4–115.4) | 140.6 (135.9–145.4) |
Men | Women | |||
---|---|---|---|---|
r (95% CI) | p value | r (95% CI) | p value | |
Ely study | ||||
Correlations with log LAR | ||||
Log fasting insulin | 0.57 (0.50, 0.64) | 1.9 × 10−32
| 0.51 (0.45, 0.57) | 7.5 × 10-36
|
Log HOMA-S | −0.58 (−0.64, −0.50) | 4.5 × 10−33
| −0.51 (−0.58, −0.45) | 2.8 × 10−36
|
EGIR RISC study | ||||
Correlations with log LAR | ||||
Log fasting insulin | 0.66 (0.60–0.70) | 4.5 × 10−67
| 0.62 (0.57, 0.66) | 1.5 × 10−73
|
Log HOMA-S | −0.65 (−0.70, −0.60) | 1.1 × 10−66
| −0.61 (−0.66, −0.57) | 2.5 × 10−73
|
Correlations with log M/I
| ||||
Log fasting insulin | −0.52 (−0.58, −0.46) | 1.4 × 10−38
| −0.46 (−0.52, −0.40) | 1.8 × 10−37
|
Log HOMA-S | 0.51 (0.45–0.57) | 2.5 × 10−37
| 0.45 (0.39, 0.51) | 5.9 × 10−36
|
Log LAR | −0.52 (−0.58,−0.45) | 4.5 × 10−38
| −0.47 (−0.53, −0.41) | 6.6 × 10−40
|